Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 8213 results

  1. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development Reference number: GID-TA10971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development Reference number: GID-TA11438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development Reference number: GID-TA11428 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Lutetium (177Lu) oxodotreotide for treating SSTR-positive advanced or inoperable gastroenteropancreatic neuroendocrine tumours in people 12 to 17 years [TSID12154]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Risankizumab for treating moderate to severe plaque psoriasis in people 6 to 17 years [TSID12204]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Rezafungin for preventing invasive fungal infections after an allogeneic blood and marrow transplant [TSID12165]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in children 4 to 11 years [TSID12190]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [TSID12216]

    Awaiting development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Tildrakizumab for treating active psoriatic arthritis [TSID12218]

    Awaiting development Reference number: GID-TA11807 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Secukinumab for treating relapsed polymyalgia rheumatica [ID6599]

    Awaiting development Reference number: GID-TA11806 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]

    Awaiting development Reference number: GID-TA11581 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]

    Awaiting development Reference number: GID-TA11594 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development